+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Alzheimer's Disease Drugs Market Research Report by Drug Class (Cholinergic, Combined Drug, and Memantine), Distribution Channel, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • PDF Icon

    Report

  • 246 Pages
  • July 2022
  • Region: Global
  • 360iResearch™
  • ID: 4905145
UP TO OFF until Dec 31st 2022
The Global Alzheimer's Disease Drugs Market size was estimated at USD 3,568.36 million in 2021, USD 3,919.03 million in 2022, and is projected to grow at a CAGR 10.00% to reach USD 6,323.07 million by 2027.

Market Statistics:


The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Alzheimer's Disease Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Drug Class, the market was studied across Cholinergic, Combined Drug, and Memantine.
  • Based on Distribution Channel, the market was studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:


We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Alzheimer's Disease Drugs market considering the current update on the conflict and its global response.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Alzheimer's Disease Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Alzheimer's Disease Drugs Market, including AB Science, AbbVie, Inc, AC Immune SA, Amgen Inc., Amneal Pharmaceuticals, Avanir Pharmaceuticals Inc., Axsome Therapeutics, Inc., AZ Therapies, Inc, BioArctic Neuroscience, Biogen, Inc, Biohaven Pharmaceuticals, Inc, Cortexyme, Eli Lilly and Company, F. Hoffmann-La Roche AG, GE Healthcare, Genentech, Inc., Green Valley Pharmaceuticals, Grifols, S.A., H. Lundbeck A/S, Janssen Pharmaceutica, Lupin Limited, Merz Holding GmbH & Co KG, Mylan N.V., Novartis AG, Otsuka Pharmaceutical Co., Ltd, Pfizer Inc., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., The Takeda Pharmaceutical Company Limited, and vTv Therapeutics Inc.

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global Alzheimer's Disease Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Alzheimer's Disease Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Alzheimer's Disease Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Alzheimer's Disease Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Alzheimer's Disease Drugs Market?
6. What is the market share of the leading vendors in the Global Alzheimer's Disease Drugs Market?
7. What modes and strategic moves are considered suitable for entering the Global Alzheimer's Disease Drugs Market?
Frequently Asked Questions about the Global Alzheimer Disease Drugs Market

What is the estimated value of the Global Alzheimer Disease Drugs Market?

The Global Alzheimer Disease Drugs Market was estimated to be valued at $3568.36 Million in 2021.

What is the growth rate of the Global Alzheimer Disease Drugs Market?

The growth rate of the Global Alzheimer Disease Drugs Market is 10.0%, with an estimated value of $6323.07 Million by 2027.

What is the forecasted size of the Global Alzheimer Disease Drugs Market?

The Global Alzheimer Disease Drugs Market is estimated to be worth $6323.07 Million by 2027.

Who are the key companies in the Global Alzheimer Disease Drugs Market?

Key companies in the Global Alzheimer Disease Drugs Market include AB Science, AbbVie, Inc, AC Immune SA, Amgen Inc., Amneal Pharmaceuticals, Avanir Pharmaceuticals Inc., Axsome Therapeutics, Inc., AZ Therapies, Inc and Biogen, Inc.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing incidences of neurological disorder
5.1.1.2. Rising awareness regarding Alzheimer’s treatment
5.1.1.3. Availability of cost-effective medicine for the treatment of Alzheimer
5.1.2. Restraints
5.1.2.1. High cost of R&D activities for drug development
5.1.3. Opportunities
5.1.3.1. Advances in the treatment of Alzheimer's diseases
5.1.3.2. Adoption of online pharmacies and advantages offered by online channels
5.1.4. Challenges
5.1.4.1. Side effect associated with Alzheimer’s drugs
5.2. Cumulative Impact of COVID-19
6. Alzheimer's Disease Drugs Market, by Drug Class
6.1. Introduction
6.2. Cholinergic
6.3. Combined Drug
6.4. Memantine
7. Alzheimer's Disease Drugs Market, by Distribution Channel
7.1. Introduction
7.2. Hospital Pharmacy
7.3. Online Pharmacy
7.4. Retail Pharmacy
8. Americas Alzheimer's Disease Drugs Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Alzheimer's Disease Drugs Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
10. Europe, Middle East & Africa Alzheimer's Disease Drugs Market
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion
12. Company Usability Profiles
12.1. AB Science
12.2. AbbVie, Inc
12.3. AC Immune SA
12.4. Amgen Inc.
12.5. Amneal Pharmaceuticals
12.6. Avanir Pharmaceuticals Inc.
12.7. Axsome Therapeutics, Inc.
12.8. AZ Therapies, Inc
12.9. BioArctic Neuroscience
12.10. Biogen, Inc
12.11. Biohaven Pharmaceuticals, Inc
12.12. Cortexyme
12.13. Eli Lilly and Company
12.14. F. Hoffmann-La Roche AG
12.15. GE Healthcare
12.16. Genentech, Inc.
12.17. Green Valley Pharmaceuticals
12.18. Grifols, S.A.
12.19. H. Lundbeck A/S
12.20. Janssen Pharmaceutica
12.21. Lupin Limited
12.22. Merz Holding GmbH & Co KG
12.23. Mylan N.V.
12.24. Novartis AG
12.25. Otsuka Pharmaceutical Co., Ltd
12.26. Pfizer Inc.
12.27. Sun Pharmaceutical Industries Limited
12.28. Teva Pharmaceutical Industries Ltd.
12.29. The Takeda Pharmaceutical Company Limited
12.30. vTv Therapeutics Inc
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2021 VS 2027 (USD MILLION)
FIGURE 3. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 4. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY REGION, 2021 VS 2027 (%)
FIGURE 5. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 6. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY REGION, 2027
FIGURE 7. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET DYNAMICS
FIGURE 8. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2021 VS 2027 (%)
FIGURE 9. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2021 VS 2027 (USD MILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2027
FIGURE 11. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY CHOLINERGIC, 2019-2027 (USD MILLION)
FIGURE 12. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY CHOLINERGIC, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 13. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COMBINED DRUG, 2019-2027 (USD MILLION)
FIGURE 14. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COMBINED DRUG, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 15. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MEMANTINE, 2019-2027 (USD MILLION)
FIGURE 16. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MEMANTINE, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 17. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2021 VS 2027 (%)
FIGURE 18. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2021 VS 2027 (USD MILLION)
FIGURE 19. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2027
FIGURE 20. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2019-2027 (USD MILLION)
FIGURE 21. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 22. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2019-2027 (USD MILLION)
FIGURE 23. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 24. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2019-2027 (USD MILLION)
FIGURE 25. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 26. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 27. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 28. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 29. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2027
FIGURE 30. ARGENTINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 31. BRAZIL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 32. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 33. MEXICO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 34. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 35. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 36. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 37. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY STATE, 2027
FIGURE 38. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 39. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 40. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 41. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2027
FIGURE 42. AUSTRALIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 43. CHINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 44. INDIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 45. INDONESIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 46. JAPAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 47. MALAYSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 48. PHILIPPINES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 49. SINGAPORE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 50. SOUTH KOREA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 51. TAIWAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 52. THAILAND ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 53. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 54. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 55. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 56. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2027
FIGURE 57. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 58. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 59. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 60. NETHERLANDS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 61. QATAR ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 62. RUSSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 63. SAUDI ARABIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 64. SOUTH AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 65. SPAIN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 66. UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 67. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 68. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 69. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 70. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET, BY TYPE
List of Tables
TABLE 1. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 4. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY REGION, 2019-2027 (USD MILLION)
TABLE 5. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 6. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY CHOLINERGIC, BY REGION, 2019-2027 (USD MILLION)
TABLE 7. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY CHOLINERGIC, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 8. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY CHOLINERGIC, BY STATE, 2019-2027 (USD MILLION)
TABLE 9. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY CHOLINERGIC, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 10. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY CHOLINERGIC, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 11. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COMBINED DRUG, BY REGION, 2019-2027 (USD MILLION)
TABLE 12. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COMBINED DRUG, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 13. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COMBINED DRUG, BY STATE, 2019-2027 (USD MILLION)
TABLE 14. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COMBINED DRUG, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 15. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COMBINED DRUG, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 16. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MEMANTINE, BY REGION, 2019-2027 (USD MILLION)
TABLE 17. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MEMANTINE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 18. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MEMANTINE, BY STATE, 2019-2027 (USD MILLION)
TABLE 19. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MEMANTINE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 20. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MEMANTINE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 21. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 22. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2019-2027 (USD MILLION)
TABLE 23. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 24. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY STATE, 2019-2027 (USD MILLION)
TABLE 25. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 26. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 27. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2019-2027 (USD MILLION)
TABLE 28. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 29. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY STATE, 2019-2027 (USD MILLION)
TABLE 30. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 31. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 32. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2019-2027 (USD MILLION)
TABLE 33. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 34. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY STATE, 2019-2027 (USD MILLION)
TABLE 35. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 36. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 37. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 38. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 39. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 40. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 41. ARGENTINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 42. ARGENTINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 43. ARGENTINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 44. BRAZIL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 45. BRAZIL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 46. BRAZIL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 47. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 48. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 49. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 50. MEXICO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 51. MEXICO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 52. MEXICO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 53. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 54. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY STATE, 2019-2027 (USD MILLION)
TABLE 55. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 56. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 57. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 58. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 59. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 60. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 61. AUSTRALIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 62. AUSTRALIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 63. AUSTRALIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 64. CHINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 65. CHINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 66. CHINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 67. INDIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 68. INDIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 69. INDIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 70. INDONESIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 71. INDONESIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 72. INDONESIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 73. JAPAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 74. JAPAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 75. JAPAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 76. MALAYSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 77. MALAYSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 78. MALAYSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 79. PHILIPPINES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 80. PHILIPPINES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 81. PHILIPPINES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 82. SINGAPORE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 83. SINGAPORE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 84. SINGAPORE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 85. SOUTH KOREA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 86. SOUTH KOREA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 87. SOUTH KOREA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 88. TAIWAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 89. TAIWAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 90. TAIWAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 91. THAILAND ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 92. THAILAND ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 93. THAILAND ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 98. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 99. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 100. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 101. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 102. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 103. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 104. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 105. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 106. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 107. NETHERLANDS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 108. NETHERLANDS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 109. NETHERLANDS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 110. QATAR ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 111. QATAR ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 112. QATAR ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 113. RUSSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 114. RUSSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 115. RUSSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 116. SAUDI ARABIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 117. SAUDI ARABIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 118. SAUDI ARABIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 119. SOUTH AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 120. SOUTH AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 121. SOUTH AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 122. SPAIN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 123. SPAIN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 124. SPAIN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 125. UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 126. UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 127. UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 128. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 129. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 130. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 131. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET: FPNV POSITIONING MATRIX - SCORES, 2021
TABLE 132. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2021
TABLE 133. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2021
TABLE 134. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET RANKING
TABLE 135. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2021
TABLE 136. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET MERGER & ACQUISITION
TABLE 137. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 138. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 139. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET INVESTMENT & FUNDING
TABLE 140. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 141. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET: LICENSE & PRICING

Companies Mentioned

  • AB Science
  • AbbVie, Inc
  • AC Immune SA
  • Amgen Inc.
  • Amneal Pharmaceuticals
  • Avanir Pharmaceuticals Inc.
  • Axsome Therapeutics, Inc.
  • AZ Therapies, Inc
  • BioArctic Neuroscience
  • Biogen, Inc
  • Biohaven Pharmaceuticals, Inc
  • Cortexyme
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GE Healthcare
  • Genentech, Inc.
  • Green Valley Pharmaceuticals
  • Grifols, S.A.
  • H. Lundbeck A/S
  • Janssen Pharmaceutica
  • Lupin Limited
  • Merz Holding GmbH & Co KG
  • Mylan N.V.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • The Takeda Pharmaceutical Company Limited
  • vTv Therapeutics Inc

Methodology

Loading
LOADING...